Immuneering Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immuneering Corporation (IMRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-61.04-53.47-50.51-33.54-17.04
Depreciation & Amortization0.390.350.280.160.08
Deferred Income Tax0.000.000.00-0.310.00
Stock Based Compensation6.505.734.061.801.09
Change in Working Capital-0.93-0.971.720.981.25
Change in Accounts Receivable0.000.010.230.28-0.29
Change in Accounts Payable-0.11-1.111.76-0.131.19
Change in Other Working Capital-0.810.12-0.280.750.36
Other Operating Activities0.080.413.941.720.00
Net Cash from Operating Activities-55.00-48.97-44.10-30.85-14.62
Investing Activities
Capital Expenditures-0.08-0.34-0.740.06-0.05
Acquisitions0.000.000.000.070.00
Purchases of Investments-5.41-44.66-50.10-75.630.00
Sales/Maturities of Investments31.9352.3092.68-75.630.00
Net Cash from Investing Activities26.437.3041.83-75.62-0.05
Financing Activities
Common Stock Issued4.2428.200.30120.320.00
Other Financing Activities-0.04-0.20-0.28-2.120.00
Net Cash from Financing Activities5.3028.440.02144.2637.98
Summary
Net Change in Cash-23.26-13.23-2.2537.8023.31
Cash at Beginning of Period59.4172.6474.8937.090.00
Cash at End of Period36.1459.4172.6474.890.00
Free Cash Flow-55.08-49.31-44.84-30.91-14.67